Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia

Background The impact on quality of life of allogeneic stem cell transplantation or conventional chemotherapy in patients with acute myeloid leukemia remains unclear, mainly because of a lack of studies with long-term follow-up. The German AML-Intergroup, therefore, initiated a survey on quality of life of patients with a relapse-free survival of at least 5 years after first-line treatment. Design and Methods The EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics was used. The questionnaire was returned by 419 of 818 patients (51.2%) identified by six study groups. The patients’ median age at diagnosis was 42 years, and the median follow-up period was 8 years. One hundred and seventy patients were treated with stem cell transplantation (121 allogenic, 49 autologous) in first complete remission; the other 249 patients were treated with conventional chemotherapy. Results The ECOG activity index revealed normal activity in 45% vs. 60% of the patients in the allogeneic stem cell transplantation vs. conventional chemotherapy groups, respectively and disabled person status in 60% vs. 35%. All QLQ-C30 functions, except physical functioning and pain, were poorer in allogeneic stem cell transplantation patients. Problems in leisure-time activities, social life, and financial management, sexual limitations and adverse effects were significantly more frequent in patients after allogeneic stem cell transplantation than after conventional chemotherapy. Multivariate logistic regression models on global health status revealed concomitant disease, age >45 years, and allogeneic stem cell transplantation as significant risk factors. Conclusions These results indicate that, compared to conventional chemotherapy, allogeneic stem cell transplantation has a significantly worse long-term impact on quality of life. This needs to be considered when treatment options are discussed.

[1]  K. Döhner,et al.  Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG. , 2006 .

[2]  A. Ganser,et al.  Treatment of Patients up to 60 Years with High Risk AML: Final Results of the AML SHG-Hannover 01/99 Trial. , 2006 .

[3]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Henze,et al.  Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials , 2005, Leukemia.

[5]  J. Blanch,et al.  Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Andrykowski,et al.  Positive and negative psychosocial sequelae of bone marrow transplantation: Implications for quality of life assessment , 1996, Journal of Behavioral Medicine.

[7]  K. Döhner,et al.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Fayers,et al.  A prospective study of health-related quality of life, fatigue, anxiety and depression 3–5 years after stem cell transplantation , 2004, Bone Marrow Transplantation.

[9]  M. Watson,et al.  Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial. , 2004, European journal of cancer.

[10]  Jacqueline Kerr,et al.  Quality of Life Following Breast‐Conserving Therapy or Mastectomy: Results of a 5‐Year Prospective Study , 2004, The breast journal.

[11]  A. Ganser,et al.  Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: results of a prospective multicenter trial , 2004, Annals of Hematology.

[12]  Alberto Redaelli,et al.  Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life. , 2004, Cancer treatment reviews.

[13]  Chiun Hsu,et al.  Survival-weighted health profile for long-term survivors of acute myelogenous leukemia , 2003, Quality of Life Research.

[14]  M. King.  The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 , 1996, Quality of Life Research.

[15]  J. Engel,et al.  Predictors of Quality of Life of Breast Cancer Patients , 2003, Acta oncologica.

[16]  L. Robison,et al.  Late‐effects among survivors of leukaemia and lymphoma during childhood and adolescence , 2003, British journal of haematology.

[17]  J. Engel,et al.  Quality of Life in Rectal Cancer Patients: A Four-Year Prospective Study , 2003, Annals of surgery.

[18]  S. Fröhling,et al.  Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.

[19]  H. Dombret,et al.  Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.

[20]  H. Döhner,et al.  Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. , 2002, Leukemia research.

[21]  P. Höcker,et al.  Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[22]  B. Brennan,et al.  Endocrine late effects after bone marrow transplant. , 2002, British journal of haematology.

[23]  H. Dombret,et al.  A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .

[24]  M. Minden,et al.  Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Berdel,et al.  Fatigue as an important aspect of quality of life in patients with acute myeloid leukemia. , 2002, Leukemia research.

[26]  K. Sullivan,et al.  Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. , 2001, Blood.

[27]  G. Ehninger,et al.  Mutations in ras proto‐oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia , 2001, British journal of haematology.

[28]  D. Fairclough,et al.  Recovery after stem-cell transplantation for hematologic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Gray,et al.  Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone , 1999, Cancer.

[30]  W. Hiddemann,et al.  Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.

[31]  T. Büchner,et al.  Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy – a longitudinal study , 1998, Leukemia.

[32]  B. Craven,et al.  Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year , 1998, Bone Marrow Transplantation.

[33]  M. Björkholm,et al.  Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation – a prospective study , 1997, Bone Marrow Transplantation.

[34]  F. Mandelli,et al.  Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial , 1997, Bone Marrow Transplantation.

[35]  M. Bullinger.  [Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine]. , 1997, Psychotherapie, Psychosomatik, medizinische Psychologie.

[36]  G. Schiller,et al.  Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors. , 1996, Psychosomatics.

[37]  M. Stauch,et al.  Long-Term Results in Adult AML: Comparison of Postremission Chemotherapy vs. Autologous BMT vs. Allogeneic BMT , 1996 .

[38]  W. Hiddemann.  Acute leukemias V : experimental approaches and management of refractory disease , 1996 .

[39]  Andrew Bottomley,et al.  EORTC QLQ-C30 Scoring Manual , 1995 .

[40]  K. Young,et al.  Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data. , 1993, Oncology nursing forum.

[41]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[42]  J. Holland,et al.  Long‐term psychological adjustment of acute leukemia survivors: impact of bone marrow transplantation versus conventional chemotherapy. , 1992, Psychosomatic medicine.

[43]  W. Hiddemann,et al.  Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[45]  E. Freireich,et al.  Treatment of acute leukemia in protected environment units , 1979, Cancer.